**IBD** SPOTLIGHT



FERRING


PHARMACEUTICALS

...e-medicine is to become the 'new normal' in IBD patient care?

E-medicine systems\* have been crucial in the management of patients during the COVID-19 pandemic<sup>1</sup>

A survey of 802 IBD HCPs from 56 countries reported that e-medicine consultations quadrupled during the COVID-19 pandemic and are anticipated to make-up around 1/3 of consultations after the pandemic<sup>1</sup>

Figure adapted from Lees et al. 2020 \*systems could include: virtual clinics; web or smartphone-based applications; and assessment of faecal calprotectin at home<sup>1,2</sup>



The digital implementation of evidence-based approaches and algorithms to managing IBD can drive up standards of care globally and improve patient outcomes<sup>1</sup>

IBD: inflammatory bowel disease; HCPs: healthcare professionals1. Lees CW et al. Gastroenterology 2020;159:805-808.2. Khorshid M et al. J Digestive Diseases 2020;21:597-599.

CA-GAS-2100009

FERRING and the FERRING PHARMACEUTICALS logo are trademarks of Ferring B.V. © 2021 Ferring B.V.